BPC-157

• Form: Lyophilized peptide
• Net per vial: [CONFIRM — common SKU sizes: 5 mg / 10 mg]
• Purity: ≥99% (HPLC-verified)
• Identity: MS-verified (per COA)
• Storage: 2–8 °C, protect from light
• Formula / M.W.: C₆₂H₉₈N₁₆O₂₂ / 1419.55 Da
• CAS: 137525-51-0

BPC-157 was characterized by Croatian researchers in the early 1990s as a stable fragment of body protective compound, a larger protein found in gastric juice. What set it apart immediately was its stability in acidic gastric environments and its activity without a carrier protein — properties that made it accessible for a wide range of preclinical models.

The peptide's broad-tissue activity is unusual. Published animal studies report effects on smooth muscle, tendon, ligament, bone, gut mucosa, and vascular endothelium, with mechanistic work pointing to nitric-oxide pathway modulation and pro-angiogenic VEGFR2 signaling. This combination makes BPC-157 a frequent reference compound in repair and cytoprotection research, including studies modeling NSAID-induced gastric injury where conventional models have struggled to find responsive tools.

• Gastrointestinal Cytoprotection — Animal studies report protective effects against NSAID-induced and stress-induced gastric lesions, with researchers attributing the activity to nitric oxide pathway modulation and mucosal repair signaling.
• Tendon & Ligament Repair — Published rodent models, including transected Achilles tendon and medial collateral ligament studies, have reported accelerated reorganization of collagen and fibroblast migration in BPC-157-treated groups versus controls.
• Angiogenesis & Vascular Remodeling — Preclinical work has documented upregulation of VEGFR2 expression and improved capillary density in injury models, supporting investigation into BPC-157's role in tissue vascularization research.
• Neuroprotection — Animal models of traumatic brain injury, peripheral nerve transection, and ischemic insult have reported reduced lesion progression and improved functional recovery in BPC-157 cohorts, generating ongoing interest in CNS repair research.
• Anti-Inflammatory Modulation — Studies have measured reductions in pro-inflammatory cytokine expression and improved outcomes in colitis and arthritis models, framing BPC-157 as a candidate for investigation into systemic inflammatory responses.

Researchers working with BPC-157 often investigate it alongside:

• TB-500 — Thymosin β4 fragment studied for cellular migration and angiogenesis; the most common pairing in published soft-tissue repair research and the basis of our Wolverine Stack (see below).
• GHK-Cu — Copper tripeptide investigated for ECM remodeling and wound repair; complements BPC-157's cytoprotective profile with a copper-mediated gene-expression angle, and pairs with both compounds in our Glow Stack.
• Wolverine Stack — Combined BPC-157 + TB-500 research blend for groups studying repair pathways in parallel.
• Retatrutide (GLP-3) — BPC-157's activity in NAFLD and MASH models pairs with hepatic-lipid research using Retatrutide.

How is BPC-157 different from TB-500?

Both are studied in tissue repair contexts but engage different pathways. BPC-157 is a 15-amino-acid pentadecapeptide derived from gastric BPC, with mechanistic work focused on nitric oxide signaling and VEGFR2-mediated angiogenesis. TB-500 is a synthetic fragment of thymosin β4 and is studied primarily for actin-binding-driven cell migration. Many research designs use them together to model complementary repair pathways.

Is BPC-157 naturally occurring?

Partially. The 15-amino-acid sequence corresponds to a region of body protective compound, a protein identified in human gastric juice. The synthetic peptide sold for research is the isolated pentadecapeptide fragment — it does not occur as a free peptide in nature, but its sequence is drawn from a naturally occurring parent protein.

What is the evidence base for BPC-157?

The published preclinical literature spans more than three decades and over 100 animal studies across gastrointestinal, musculoskeletal, vascular, and neural models. A 2022 pharmacokinetic study in Frontiers in Pharmacology characterized distribution and metabolism in rats and dogs. Human clinical data remain limited, with most evidence drawn from rodent and other animal models.